Home›Trial›NCT05923073
🔬NCT05923073Phase 3RECRUITING

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Study Summary

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

Conditions
Crohn's Disease
Interventions / Drugs
GuselkumabGuselkumab
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment120 participants
Primary Completion—
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.551095+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.